Perindopril treatment affects both preglomerular renal vascular lumen dimensions and in vivo responsiveness to vasoconstrictors in spontaneously hypertensive rats

Hypertension
G BergströmWarwick P Anderson

Abstract

We have previously shown that chronic treatment with angiotensin-converting enzyme inhibition (ACEI) did not reverse hypertrophy of the renal arterial wall in spontaneously hypertensive rats (SHR). In this study we determined the effects of perindopril on the functional properties of the renal vasculature in vivo and on its resistance to flow at maximal dilatation in vitro, a measure of vessel lumen diameter. Two groups of SHR were studied: untreated or treated with perindopril (3 mg/kg per day) in their drinking water from 4 weeks of age. At 10 weeks, (1) vessel lumen characteristics were assessed using a maximally dilated in vitro isolated kidney perfusion and (2) the renal vasoconstrictor responses to bolus doses of vasoactive agents (angiotensin II and phenylephrine) administered into the renal artery were measured in vivo (anesthetized rats). Mean arterial pressure was significantly lower in conscious SHR treated with perindopril (132+/-2 versus 97+/-2 mm Hg, P<.001). In vitro, the pressure-flow relationship and the pressure-glomerular filtration rate relationship were both shifted significantly to the left (P<.001). The perindopril-treated kidneys began filtering at a significantly lower threshold perfusion pressure than ...Continue Reading

References

Jun 1, 1977·Acta Physiologica Scandinavica·B FolkowS E Ricksten
Apr 1, 1988·Journal of Applied Physiology·H A Feldman
Jun 1, 1971·The American Journal of Physiology·G J KaloyanidesP Raskin
Apr 1, 1982·Physiological Reviews·B Folkow
May 1, 1983·Acta Physiologica Scandinavica·S Grimnes
Jan 1, 1983·Hypertension·V H GattoneF C Luft

❮ Previous
Next ❯

Citations

Feb 21, 2004·European Journal of Pharmacology·Erika I BoesenMichelle M Kett
Mar 21, 2002·Clinical and Experimental Pharmacology & Physiology·A EdgleyW Anderson
Jan 25, 2003·Clinical and Experimental Pharmacology & Physiology·H J DunstanM J Black
Aug 2, 2003·Clinical and Experimental Pharmacology & Physiology·Erika I BoesenWarwick P Anderson
Mar 22, 2002·The New England Journal of Medicine·Richard J JohnsonBernardo Rodriguez-Iturbe
Jul 11, 2003·Cardiology in Review·John KanellisRichard J Johnson
Mar 4, 2005·Clinical and Experimental Pharmacology & Physiology·Hiroyuki KinunoHiroshi Inoue
Jan 30, 2014·Clinical and Experimental Pharmacology & Physiology·Hidenori YamazakiFuyuhiko Nishijima
Dec 25, 2008·American Journal of Physiology. Renal Physiology·Amany ShwetaJohn F Bertram
Jan 15, 2002·American Journal of Physiology. Renal Physiology·Bernardo Rodríguez-IturbeHéctor A Pons
Oct 3, 1999·Physiological Reviews·J Zicha, J Kunes
Jun 21, 2003·Journal of Hypertension·Amanda J EdgleyWarwick P Anderson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.